Home/Pipeline/dl-3-n-Butylphthalide (NBP) Soft Capsules

dl-3-n-Butylphthalide (NBP) Soft Capsules

Ischemic Stroke

Phase 3Active (US trials with FDA orphan drug designation)

Key Facts

Indication

Ischemic Stroke

Phase

Phase 3

Status

Active (US trials with FDA orphan drug designation)

Company

CSPC Pharmaceutical

About CSPC Pharmaceutical

Leading Chinese pharmaceutical company with innovative stroke drug dl-3-n-Butylphthalide advancing in US Phase 3 trials with FDA orphan drug designation.

View full company profile

Therapeutic Areas

Neurology Cardiovascular Infectious Disease Oncology

Other Ischemic Stroke Drugs

Drug	Company	Phase	Status
MultiStem	Athersys	Phase 3	Active (subject to funding)
IQool™ System	BrainCool	Clinical Evaluation	Evidence Generation
itMSCs + itNSCs	Stemedica Cell Technologies	Research	Active
BXT-25	BioXyTran	Preclinical	Active
Ischemic Stroke Program	CHS Pharma	Pre-clinical	Active
3K3A-APC	ZZ Biotech	Phase 2/3	Active
Ischemic Stroke Device(s)	Infinity Neuro	Pre-clinical	Active
THDG3	DeckTherapeutics	Pre-clinical	Active
Prometheus-based Gene Therapy	Remedium Bio	Pre-clinical	Active
iNstroke Catheters	iVascularU	Commercial	Active
Dual Thrombolytic Regimen (tPA + HisproUK)	Thrombolytic Science International	Phase 2	Active
Neural Stem Cell Therapy for Stroke	Neoneuron	Pre-clinical	Active